A small molecule drug as a topical treatment for small fiber peripheral neuropathy
Inventors: Gabriel Corfas, Joshua Murtie
Invention Types: Therapeutics
Research Areas: Endocrinology, Neurology/Neuroscience
Keywords: Drug Discovery, Drug Screening, Small Molecule/DrugFor More Information Contact: Caron, Connie
A small molecule that enhances ligand-induced signaling by the Glial Derived Neurotrophic Factor receptor (GFR-alpha/RET)Â family, which when applied topically in mouse models of small fiber peripheral neuropathy prevents nerve degeneration and preserves sensory function.
Peripheral neuropathy is very prevalent and can be caused by many diseases and disorders. Applications include neuropathies caused by:|
There are no products currently available to directly treat the underlying causes of nerve damage; the current treatments (antidepressants, anticonvulsants, lidocaine patches) only alleviate the symptoms but do not treat the associated nerve damage or address the disease that has neuropathy as a side effect. The topical use is expected to be safer and have fewer side effects than the oral administration.
• Exclusive License
• Partnerships for Development
Key Publications: Manuscript in press (PNAS)
Related Publications: Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, Benoit-Marand M, Chen C, Moore H, O'Donnell P, Brunner D, Corfas G. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for the pathogenesis of neuropsychiatric disorders, Proc Natl Acad Sci USA 2007; 104: 8131-8136.